HLA-C Mismatch without Impact on Outcome after Allogeneic HSCT  by Mattsson, Jonas et al.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S147eS170S160in the homo-to-homo SCT group, hetero-to-homo SCT may
be considered when immediate transplantation is required
but an appropriate alternative donor is not available oth-
erwise.194
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In the present retrospective study we analyzed 382 patients
undergoing HSCT between 1995 and 2011. Of these 115 pa-
tients received an HLA-CmmHSCTand 266 received an HLA-
C matched graft. Only patients with malignant disease were
included in the analysis with no signiﬁcant differences be-
tween patients with HLA-C matched or mm donors. Median
age was 42 (<1-68) versus 41 (<1-65) years in the matched
and mm groups respectively. Early/late disease was 119/147
and 51/64, respectively (ns). Reduced intensity conditioning
was given to 100 patients (38%) among HLA-C matched pa-
tients compared to 42 (37%) in the HLA-C mm group. Mye-
loablative conditioning was similar in both groups. Female
donor to male recipient was given to 20 (8%) in the matched
group versus 19 (17%) in the mm group. Bone marrow was
used as stem cell source in 74 (28%) patients in the HLA-C
matched group compared to 45 (39%) in the mm group (ns).
The remaining patients received PBSC in each group. Median
CD34 cell dose (x106/kg) was 7.2 (0.2-56.4) versus 7.1 (0.3-
28.7), respectively. GVHD prophylaxis consisted of CsA +MTX
in 84% versus 85% of the patients in each group. ATG was
given to all patients before HSCT.
In the present material graft failure (GF) occurred in 9
(3.4%) in HLA-C matched group compared to 7 (6.1%) in the
mm group (ns). In multivariate analysis for GF, major AB0
mismatch (p¼0.03), RIC (p¼0.01) and female donor to male
recipient (p¼0.002) were signiﬁcant risk factors. HLA-C mm
was not found to be signiﬁcant (p¼0.71). Neither had HLA-C
mm any impact onmortality. Signiﬁcant factors associated to
mortality in multivariate analysis were: disease stage
(p<0.001), year of HSCT (p¼0.015) and donor age (p<0.001).
For acute GVHD grades II-IV CsA+MTX (p<0.001) and RIC
(p<0.001) decreased the risk whereas the use of PBSC
(p¼0.016) increased the risk. HLA-C matched patients
compared to HLA-C mm showed no statistical difference
regarding TRM, RFS, mortality, acute GVHD grades II-IV and
relapse incidence. We also analyzed MFI for all HLA-C alleles
which showed no signiﬁcant correlation to outcome.
In conclusion, in the present study we ﬁnd no negative
impact of HLA-C mismatch on outcome after HSCT.195
Successful Engraftment and Full Donor Chimerism in
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Background: Patients with graft failure or disease relapse
following allogeneic hematopoietic cell transplant (HCT)
have <10% survival with no intervention. Second HCT in this
situation is becoming more common. Advantages of cordblood (UCB) in this setting include prompt availability of
donor cells, no donor risk during cell procurement, and po-
tential of enhancing the graft versus leukemia effect through
use of highly mismatched grafts. We sought to determine the
feasibility of second allogeneic transplant with UCB.
Methods: Twenty-three patients median age 33 yrs (range
4-69 yrs) received a CB transplant (CBT) as a second alloge-
neic HCT at the Fred Hutchinson Cancer Research Center
between 2006e2013. Indication for second allograft were
relapse (n ¼ 19), graft failure (n ¼ 3) and donor derived MDS
(n ¼ 1). Median time between transplants was 505 days
(range, 55-3515). At the time of second HCT, 19 patients were
in CR and 4 patients had persistent disease. For their second
transplant, 10 patients received reduced intensity condi-
tioning (RIC) with ﬂudarabine (Flu) 200mg/m2, cyclophos-
phamide (Cy) 50 mg/kg and 200-400 cGy TBI, 2 patients
received myeloablative (MAC) conditioning with Flu 75mg/
m2, Cy 120mg/kg and 1200-1320cGy TBI (n ¼ 2), and 11
patients received “midi” conditioning with treosulfan 42mg/
kg, Flu 150-200mg/m2 and 200 cGy TBI. All patients received
GVHD prophylaxis with cyclosporine and mycophenolate
mofeteil. Twenty of the 23 patients received a double CBT
with a median TNC of 4.8 x 107 cells/kg and a median CD34+
of 2.2 x 105 cells/kg. Twelve patients received at least one 4/6
graft; 9 patients received at least one 5/6 graft.
Results:Median time to engraftment was 22 days (range day
6-49) among 21 evaluable patients; 2 patients died prior to
engraftment. Median time to platelet engraftment was 55
days (range 23-83). Day +28 CD3+ chimerism was 100%
second transplant donor in 16 of 19 evaluable patients, and
100% ﬁrst donor in 2. One patient was mixed between ﬁrst
(22%) and second donor (78%). Death prior to Day 100 was
seen in 5 patients (infection/organ failure (n ¼ 3), encepha-
lopathy (n ¼ 1), and relapse (n ¼ 1). Acute grade II-IV and III-
IV GVHD was diagnosed in 18 of 21 and 6 of 21 evaluable
patients respectively, and 9 of 16 evaluable patients devel-
oped chronic GVHD (6 mild, 2 moderate, 1 severe). Disease
free survival, treatment related mortality, and relapse at 2
years was 40%, 33%, and 35% respectively. Patients receiving
MAC/midi vs RIC conditioning experienced a 2-year DFS of 46
vs 15% (p ¼ 0.02) and relapse rate of 26 vs 45% (p ¼ 0.20).
Conclusions: Our results demonstrate quite favorable out-
comes in patients undergoing CBTas a second allogeneic HCT,
with all evaluable patients engrafting and full donor chime-
rism achieved in 16 of 19 patients byDay +28. The use of CB as
the stem cell source is particularly attractive in this setting as
it eliminates the need to put a conventional donor at risk.196
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Human leukocyte antigen (HLA)-mismatced/haploidentical
stem cell transplantation (SCT) is a known risk factor for
human herpesvirus 6 (HHV-6) infection. High plasma HHV-6
DNA loads in peripheral blood have been associated with the
development of HHV-6-associated encephalitis. However,
previous results have been obtained in patients who under-
went HLA-matched SCT or combined populations, including
a small number of HLA-mismatched SCTs.
